Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

MyNCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1968 1
1970 3
1971 4
1972 14
1973 8
1974 14
1975 9
1976 14
1977 20
1978 23
1979 12
1980 15
1981 11
1982 10
1983 16
1984 14
1985 20
1986 10
1987 18
1988 15
1989 11
1990 17
1991 12
1992 14
1993 17
1994 22
1995 25
1996 28
1997 31
1998 27
1999 23
2000 30
2001 30
2002 29
2003 40
2004 41
2005 73
2006 53
2007 59
2008 49
2009 60
2010 58
2011 59
2012 67
2013 49
2014 49
2015 50
2016 43
2017 47
2018 38
2019 24
2020 0
Text availability
Article attribute
Article type
Publication date

Search Results

1,339 results
Results by year
Filters applied: . Clear all
Page 1
Effective combinatorial immunotherapy for castration-resistant prostate cancer.
Lu X, Horner JW, Paul E, Shang X, Troncoso P, Deng P, Jiang S, Chang Q, Spring DJ, Sharma P, Zebala JA, Maeda DY, Wang YA, DePinho RA. Lu X, et al. Nature. 2017 Mar 30;543(7647):728-732. doi: 10.1038/nature21676. Epub 2017 Mar 20. Nature. 2017. PMID: 28321130 Free PMC article.
Immunotherapy for Prostate Cancer: Where We Are Headed.
Schepisi G, Farolfi A, Conteduca V, Martignano F, De Lisi D, Ravaglia G, Rossi L, Menna C, Bellia SR, Barone D, Gunelli R, De Giorgi U. Schepisi G, et al. Int J Mol Sci. 2017 Dec 5;18(12):2627. doi: 10.3390/ijms18122627. Int J Mol Sci. 2017. PMID: 29206214 Free PMC article. Review.
Inmunotherapy in prostate cancer.
Anselmo da Costa I, Stenzl A, Bedke J. Anselmo da Costa I, et al. Arch Esp Urol. 2019 Mar;72(2):211-222. Arch Esp Urol. 2019. PMID: 30855023 Review. English.
Prostate cancer.
Brody H. Brody H. Nature. 2015 Dec 17;528(7582):S117. doi: 10.1038/528S117a. Nature. 2015. PMID: 26672779 No abstract available.
The Immune Landscape of Prostate Cancer and Nomination of PD-L2 as a Potential Therapeutic Target.
Zhao SG, Lehrer J, Chang SL, Das R, Erho N, Liu Y, Sjöström M, Den RB, Freedland SJ, Klein EA, Karnes RJ, Schaeffer EM, Xu M, Speers C, Nguyen PL, Ross AE, Chan JM, Cooperberg MR, Carroll PR, Davicioni E, Fong L, Spratt DE, Feng FY. Zhao SG, et al. J Natl Cancer Inst. 2019 Mar 1;111(3):301-310. doi: 10.1093/jnci/djy141. J Natl Cancer Inst. 2019. PMID: 30321406
Immune mediators in the tumor microenvironment of prostate cancer.
Dai J, Lu Y, Roca H, Keller JM, Zhang J, McCauley LK, Keller ET. Dai J, et al. Chin J Cancer. 2017 Mar 14;36(1):29. doi: 10.1186/s40880-017-0198-3. Chin J Cancer. 2017. PMID: 28292326 Free PMC article. Review.
Immune-based therapies for metastatic prostate cancer: an update.
Hossain MK, Nahar K, Donkor O, Apostolopoulos V. Hossain MK, et al. Immunotherapy. 2018 Feb 1;10(4):283-298. doi: 10.2217/imt-2017-0123. Immunotherapy. 2018. PMID: 29421982 Review.
1,339 results
Jump to page
Feedback